GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Immunotech Biopharm 6978.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

0.38

0.00%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Net income

−CN¥268.8m

FY2018FY2025

Free cash flow

−CN¥130.3m

FY2018FY2025

Shareholders' equity

−CN¥16.2m

FY2018FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Gross profit−CN¥62.7m———————
Research and developmentCN¥99.4mCN¥154.2mCN¥177.3mCN¥69.8mCN¥109.0mCN¥324.5mCN¥72.2mCN¥36.3m
Operating income−CN¥261.6m−CN¥198.8m−CN¥230.5m−CN¥273.9m−CN¥401.6m−CN¥404.4m−CN¥128.3m−CN¥49.4m
Net income−CN¥268.8m−CN¥186.9m−CN¥334.8m−CN¥318.1m−CN¥412.5m−CN¥511.3m−CN¥127.0m−CN¥40.5m
Diluted earnings per share-0.45-0.36-0.65-0.62-0.80-1.01-0.33-0.08

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assetsCN¥702.5mCN¥564.0mCN¥846.3mCN¥879.4mCN¥1.28bnCN¥1.41bnCN¥485.6mCN¥325.2m
Cash and short-term investmentsCN¥180.1mCN¥57.5mCN¥177.0mCN¥79.5mCN¥411.5mCN¥984.5mCN¥328.7mCN¥202.7m
Total liabilitiesCN¥662.7mCN¥580.5mCN¥675.4mCN¥373.1mCN¥319.7mCN¥94.8mCN¥287.2mCN¥73.3m
DebtCN¥422.1mCN¥384.6mCN¥457.2mCN¥149.8mCN¥111.1mCN¥51.1mCN¥211.1mCN¥33.9m
Shareholders' equity−CN¥16.2m−CN¥13.3mCN¥173.6mCN¥508.4mCN¥957.6mCN¥1.31bnCN¥196.8mCN¥250.0m
Shares outstanding600m515m515m515m515m507m381m500m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations−CN¥113.3m−CN¥125.7m−CN¥163.6m−CN¥210.7m−CN¥296.6m−CN¥307.1m−CN¥111.2m−CN¥51.3m
Capital spending−CN¥17.0m−CN¥28.1m−CN¥22.5m−CN¥112.5m−CN¥211.1m−CN¥88.1m−CN¥24.5m−CN¥40.8m
Free cash flow−CN¥130.3m−CN¥153.8m−CN¥186.2m−CN¥323.2m−CN¥507.6m−CN¥395.2m−CN¥135.7m−CN¥92.2m
Dividends paid——————−CN¥1.1m−CN¥39.1m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022
Gross profit−CN¥27.7m−CN¥30.4m————−CN¥65.6m−CN¥58.1m
Operating income−CN¥81.2m−CN¥99.4m−CN¥101.4m−CN¥84.6m−CN¥114.0m−CN¥131.0m−CN¥115.9m−CN¥147.9m
Net income−CN¥80.2m−CN¥116.4m−CN¥150.4m−CN¥94.4m−CN¥92.5m−CN¥217.0m−CN¥137.4m−CN¥207.3m
Diluted earnings per share-0.13-0.19-0.25-0.18-0.18-0.42-0.27-0.40
Cash from operations—−CN¥64.0m−CN¥60.0m−CN¥46.0m−CN¥79.0m——−CN¥107.0m
Capital spending—−CN¥6.0m−CN¥11.0m−CN¥7.0m−CN¥19.0m——−CN¥4.0m
Free cash flow—−CN¥70.0m−CN¥71.0m−CN¥53.0m−CN¥98.0m——−CN¥111.0m
Total assetsCN¥558.7mCN¥702.5mCN¥569.4mCN¥564.0mCN¥719.7mCN¥846.3mCN¥1.21bnCN¥879.4m
Cash and short-term investmentsCN¥76.8mCN¥180.1mCN¥24.5mCN¥57.5mCN¥145.3mCN¥177.0mCN¥310.8mCN¥79.5m
DebtCN¥34.1mCN¥422.1mCN¥130.1mCN¥384.6mCN¥409.3mCN¥457.2mCN¥164.2mCN¥149.8m
Shareholders' equity−CN¥97.6m−CN¥16.2m−CN¥165.8m−CN¥13.3mCN¥81.1mCN¥173.6mCN¥454.6mCN¥508.4m

Financial ratios

Data as of 3 Nov 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Return on equity1656.4%1405.8%-192.9%-62.6%-43.1%-38.9%
Return on assets-38.3%-33.1%-39.6%-36.2%-32.3%-36.3%
Free cash flow yield-39.4%-54.2%-78.3%-46.8%-40.8%-106.0%
Earnings growth23.5%-44.2%5.3%-10.2%-19.3%302.6%
Current ratio0.35x0.20x1.05x0.57x2.29x27.95x
Debt to equity-26.02x-22.23x3.91x0.05x0.02x-0.01x
Equity ratio-2.3%-2.4%20.5%57.8%74.9%93.2%
Interest coverage-33.80x-31.28x-2.65x-44.70x-93.89x-145.57x
Buybacks as a share of market value-16.6%0.0%0.0%0.0%-1.6%-33.0%

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-1.5%-8.3%—
Net income-5.5%-12.1%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings-2.6-2.5-3.1-3.0-8.4-4.4

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.